A long-awaited clinical trial found that a headset designed to stimulate the brain with flickering lights and rhythmic sounds did not slow memory loss in people with Alzheimer’s disease. After one year, participants using Cognito Therapeutics’ Spectris AD device showed no improvement in cognitive function compared with those given a sham device, although the company said the treatment appeared more promising in people with mild cognitive impairment.
Spectris AD consists of goggles and headphones that patients wear at home for one hour each day. The flashing lights and rhythmic sounds are intended to trigger gamma waves, a type of brain activity associated with attention and memory.
At the Alzheimer’s Disease Clinical Trials Conference in Boston, Massachusetts, on November 16, Cognito Therapeutics, based in Cambridge, Massachusetts, reported that participants who used the active device for 12 months did not perform better on cognitive tests than those assigned to sham treatment.
Cognito chief executive Christian Howell said he was disappointed by the overall results, but said the findings suggested a benefit for people with mild cognitive impairment. The company plans to apply for approval from the U.S. Food and Drug Administration next year.
“The effects we observed in the mild subgroup were very meaningful,” Howell said. “It gives me a sense of optimism moving forward.”
Researchers not involved in the trial were more cautious. “The test was negative,” said Eric McDade, a neurologist at Washington University School of Medicine in St. Louis. “If anything were to happen after this, it would be a follow-up study in that milder population.”
Flashing signs
The trial randomly assigned 673 people with Alzheimer’s disease to use either an active or sham Spectris AD device for 60 minutes a day over 12 months. After one year, participants using the active device had declined by an average of 8.97 points on a 156-point scale measuring cognition and the ability to perform daily activities. Those using the sham device declined by 8.82 points.
Howell said the device appeared to work better in participants with mild cognitive impairment than in those with moderate impairment. In the mild-impairment group, decline was 41.6% slower among active-device users than among sham-device users, with an average difference of 3 points.
Rob Howard, a psychiatrist and dementia expert at University College London, said the subgroup data were exploratory rather than convincing evidence that the device is effective.
“If this were a drug, a clear failure like this would mean the company would not move forward with seeking regulatory approval,” Howard said. The device’s safety does not make it more useful to patients, he added.
Howard also noted that previous trials of Spectris AD had been unsuccessful. A small 2024 trial failed to show that the device slowed declines in cognitive and functional abilities among people with Alzheimer’s disease.1
A setback for gamma-wave research
The findings are a setback for researchers studying whether modulating gamma brain waves can improve brain health.
Source: www.nature.com












